Skip to contentN
Niagen Bioscience, Inc.
N
NAGENiagen Bioscience, Inc. Q3 2019 · 10-Q
Revenue$12.05M$12.05M+48.4% vs Q3 2018 Net Income-$7.20M-$7.20MN/M vs Q3 2018 EPS Diluted-$0.12-$0.12N/M vs Q3 2018 Gross Profit$6,749,000+54.8% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Niagen Bioscience, Inc. · CIK 1386570 · Engraved from SEC EDGAR
Operating Cash Flowderived-$7,760,000N/M Free Cash Flowderived-$7,915,000N/M Margins · derivedGross margin56.0%+2.3 pt vs Q3 2018
Operating margin-57.1%+48.7 pt vs Q3 2018
Net margin-59.8%+46.2 pt vs Q3 2018
ended Sep 30, 2019 · filed Nov 12, 2019 · 43 d after period end